Q4 Consumer Health Earnings Preview: GSK, Bayer, RB, And Sanofi
Executive SummaryGSK is looking to close out 2018 strongly as it prepares to launch its Consumer Health JV with Pfizer, while Bayer will be glad to see the back of a tough year. Elsewhere, RB is preparing for life after Rakesh Kapoor and Sanofi is ramping up its push into digital health.
You may also be interested in...
Pfizer consumer health sales up 4% to $3.6bn in 2018 as it prepares to move business into JV with GSK anticipated to close in the second half of 2019. Following 2% growth in 2017, a flat year in 2016 and a dip in 2015, Pfizer's view is confirmed of consumer health as a reliable revenue stream but not a strong growth driver.
Firm's Hindustan Unilever division will merge with s GSK Consumer Healthcare India which has had total sales around €550m so far in 2018, primarily through the Horlicks and Boost brands and with nearly 90% of the revenues in India. Also will acquire 82% stake in GSK Bangladesh and other GSK commercial operations and assets outside India, paying €3.3bn in combination of cash and shares in Hindustan Unilever.
Sanofi enjoyed “balanced growth across all geographies and key categories” at its Consumer Healthcare business in the third quarter, noted group chief executive officer Olivier Brandicourt.